大腸菌(ExPEC)ワクチンの世界市場

◆英語タイトル:MarketVIEW: E.coli (ExPEC) vaccines - Global vaccine overview
◆商品コード:VACZ51202
◆発行会社(調査会社):VacZine Analytics
◆発行日:2015年11月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,000 ⇒換算¥426,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,000 ⇒換算¥426,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,000 ⇒換算¥852,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、大腸菌(ExPEC)ワクチンの世界市場機会について調査・分析し、ExPEC疾患の概要、疫学トレンド、リスク要因、ExPEC疾患の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、大腸菌(ExPEC)ワクチンの市場規模予測結果(金額及びボリューム)などの情報をお届けいたします。
【レポートの概要】

Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in 2013 compared to 46,140 in 2000, an increase of 109%1 Although the number Streptococcal, Staphylococcal and Pneumococcal bacteraemias also increased over the same time period, in 2009, E. coli overtook Staphylococcus as the leading cause of bacteraemia. Importantly, carbapenem-resistant E. coil is also considered an “urgent” threat according to the US CDC. E.coli is also a common cause of community-acquired, uncomplicated UTIs, which are a common cause of US emergency department and primary care visits. According to NHANES III, around 12% of women reported a UTI in the last 12 months.

Currently there is no vaccine to prevent ExPEC infections. Janssen Pharmaceuticals is co-developing JNJ-860/EcoXyn-4V, a 4- valent “O” antigen conjugate vaccine (the O antigen forms part of the E. coli lipopolysaccharide), currently in Phase II development. Other approaches such as subunit or whole vaccines have under investigation but not currently in active development.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of ExPEC vaccines across major Western to 2035. Indications considered are prevention of invasive ExPEC disease in ]18 yrs (risk and non-risk) and prevention of recurrent UTIs in females 18-64 yrs.The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted by a potential vaccine.

*** THIS PRODUCT IS A EXECUTIVE PRESENTATION AND A FORECAST MODEL

【レポートの目次】

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV064_TOC_151127.pdf

****This product is composed of two forecast models and a summary presentation

Title page
Author’s note
Contents
Executive summary
ExPEC vaccines: Commercial model: key outputs
ExPEC vaccines: sales by scenario (base pricing) to 2030
ExPEC vaccines: sales by scenario (low pricing) to 2030
ExPEC vaccines: sales by scenario (high pricing) to 2030
Modelling commercial potential
The role of an ExPEC vaccine
ExPEC: disease associations
ExPEC vaccine: potential indications
ExPEC vaccine: potential target populations
ExPEC vaccine target product profile (TPP)
Key model assumptions
Key model assumptions: scenarios
Pricing assumptions: disease burden comparisons
Pricing assumptions: bacteraemias – comparator table
ExPEC – Disease background and epidemiology
The pathogen
Pathogenic types
E.coli and bacteraemias
Bacteraemias: hospital admissions – US, 2000-2013
Bacteraemias: by age group US, 2013
Bacteraemias: mortality, United Kingdom
Bacteraemias: UK comparison to other hospital pathogens
Bacteraemias: by age and gender, England
Bacteraemias: sources of, England
Bacteraemias: community-acquired, England
Bacteraemias: France
Bacteraemias: France, clinical characteristics
E.coli: infant sepsis and meningitis
E.coli and healthcare-associated infections
Urinary tract infections, uncomplicated
Urinary tract infections, uncomplicated: US burden
Urinary tract infections, uncomplicated: hospitalization
Urinary tract infections, uncomplicated: treatment
Urinary tract infections, uncomplicated: recurrence
Urinary tract infections, uncomplicated: impact
E. coli antibiotic resistance trends
E.coli – antibiotic resistance trends: global dynamics
E.coli – antibiotic resistance trends (WHO report)
EU E.coli – antibiotic resistance trends (1)
EU E.coli – antibiotic resistance trends (2)
ExPEC vaccines: R&D pipeline
Vaccine R&D pipeline: overview
Vaccine R&D pipeline: JNJ-860/EcoXyn-4V
Target risk groups for JNJ-860/EcoXyn-4V vaccine
JNJ-860/EcoXyn-4V vaccine: status
Vaccine R&D pipeline: relevance E. coli O serotypes
Vaccine R&D pipeline: other HAI infection targets
Vaccine R&D pipeline: potential clinical strategy
ExPEC vaccines: methodology
Vaccine coverage rates: case studies
Vaccine coverage rates: private self-pay
Vaccine coverage rates: pneumovax benchmarks
Demographic and epidemiological model inputs
Bibliography
VacZine Analytics
Disclaimer

*** PAGES: ~67 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form



【レポートのキーワード】

大腸菌、ExPEC、腸管外病原性大腸菌、菌血症、尿路感染症、ワクチン、治療薬

★調査レポート[大腸菌(ExPEC)ワクチンの世界市場]販売に関する免責事項
★調査レポート[大腸菌(ExPEC)ワクチンの世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆